AminM.AlousiMD

Medicine/Pediatrics • Houston, TX

M.D. Anderson Cancer Center

Join to view full profile

Dr. Alousi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Alousi's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine/Pediatrics, 1997 - 2001
Wayne State University School of MedicineClass of 1997

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 2006 - 2025
AL State Medical License 2023 - 2024
MI State Medical License 1997 - 2008
American Board of Internal Medicine Hematology
Join now to see all

Clinical Trials

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Thymoglobulin (ATG) Dose Finding Study Start of enrollment: 2006 Dec 01
Terminated
Phase 1, Phase 2
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination With Corticosteroids Start of enrollment: 2005 Aug 01
Feasibility Study of Collecting Multicenter Chronic GVHD Data Start of enrollment: 2006 Aug 01
Completed
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Photopheresis for the Treatment of Acute Graft Versus Host Disease Start of enrollment: 2008 Jan 01
Completed
Phase 2
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD) Start of enrollment: 2008 Apr 01
Terminated
Phase 2
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide Start of enrollment: 2008 Sep 01
Completed
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics Start of enrollment: 2020 Jun 01
Withdrawn
Phase 2
Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Start of enrollment: 2021 Apr 08
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

16 citations
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
Rima M Saliba, Amin M Alousi, Joseph Pidala, Mukta Arora, Stephen R Spellman
Transplantation and Cellular Therapy. 2022-10-01
2868 citations
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Vancheswaran Gopalakrishnan, Christine N. Spencer, Luigi Nezi, Alexandre Reuben, Miles C. Andrews
Science. 2018-01-05
18 citations
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
Betul Oran, Richard E. Champlin, Feng Wang, Tomoyuki Tanaka, Rima M. Saliba
Leukemia. 2021-06-16

Journal Articles

Pilot Study Using Post-Transplant Cyclophosphamide (PTCy), Tacrolimus and Mycophenolate GVHD Prophylaxis for Older Patients Receiving 10/10 HLA-Matched Unrelated Donor...
Uday R Popat, Amin Alousi, Issa F Khouri, Muzaffar Qazilbash, Richard E Champlin, Partow Kebriaei, Simrit Parmar, Chitra Hosing, Nature
Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...
Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature
A Phase II/III Randomized, Multicenter Trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for Treatment of Chronic Graft-Versus-Host Disease:...
Amin M Alousi, Mukta Arora, Luciano J Costa, Aleksandr Lazaryan, Daniel J Weisdorf, Sunil Abhyankar, Eneida R Nemecek, Haematologica

Abstracts/Posters

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Do...
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis
Amin M. Alousi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all